PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
October 1, 2024

Data from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAditya BardiaJCJavier CortésFBFrançois‐Clément Bidard

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bardia et al. (2024) studied this question.

synapsesocial.com/papers/68e5611ae2b3180350efdfddhttps://doi.org/10.1158/1078-0432.c.7474507
View Full Paper
Ask AI
Bookmark
Share